Advances in Immunotherapy of Malignant Pleural Mesothelioma
Dongying Liao, Yongchao Yu, Qingyun Mei, Ziwei Wang, Xiaojiang Li, Yingjie Jia, Fanming Kong
Abstract
Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.
Topics & Concepts
NivolumabMedicineIpilimumabImmunotherapyOncologyInternal medicineMesotheliomaCancerPathologyOccupational and environmental lung diseasesPleural and Pulmonary DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis